Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264508 | 0.86 | CACNA1H (0.60) | CACNA1HCACNA1CCACNA1BCACNA1G | |
| SCHEMBL8264541 | 0.84 | HTT (0.62) | MAPTGAAHSD17B10KDM4EPOLB | |
| SCHEMBL11810412 | 0.84 | CACNA1H (0.43) | MAPTGAAHSD17B10KDM4EPOLB | |
| SCHEMBL8305457 | 0.84 | MAPT (0.43) | MAPTGAAHSD17B10KDM4EPOLB | |
| SCHEMBL12252322 | 0.84 | RIPK1 (0.57) | MAPTGAAHSD17B10KDM4EPOLB | |
| SCHEMBL10146528 | 0.76 | PARP1 (0.56) | MAPTGAAHSD17B10HTTPARP1 | |
| SCHEMBL1285737 | 0.73 | HTT (0.47) | GAAHTTPARP1 | |
| SCHEMBL1144583 | 0.73 | SMN1; SMN2 (0.50) | MAPTGAAHSD17B10HTTPARP1 | |
| SCHEMBL1285878 | 0.73 | RPS6KA3 (0.58) | MAPTGAAHSD17B10KDM4EPOLB | |
| SCHEMBL30888946 | 0.73 | SMN1; SMN2 (0.50) | MAPTGAAHSD17B10HTTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | MAPT 1817/4885GAA 2439/4885HSD17B10 3212/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | MAPT 1824/4885GAA 2500/4885HSD17B10 3219/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | MAPT 1824/4885GAA 2500/4885HSD17B10 3219/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | MAPT 1824/4885GAA 2500/4885HSD17B10 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.